5 EASY FACTS ABOUT ABBV-744 BRD4 INHIBITOR MECHANISM OF ACTION DESCRIBED

In Segment A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to recognize Secure dosing program. More members is going to be enrolled with the recognized monotherapy dosign program. In Section B, participants will obtain oral ruxolitinib and ABBV-744 will likely be offered as "add-on" therapy. In Section C, participant